6-Hydroxy-DET

6-Hydroxy-DET
Clinical data
Other names6-HO-DET; 6-OH-DET; 6-HDET; 6-Hydroxydiethyltryptamine; 6-Hydroxy-N,N-diethyltryptamine
Routes of
administration
Intramuscular injection
Drug classSerotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Onset of action1 hour
Duration of action3–4 hours
Identifiers
  • 3-[2-(diethylamino)ethyl]-1H-indol-6-ol
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC14H20N2O
Molar mass232.327 g·mol−1
3D model (JSmol)
  • CCN(CC)CCC1=CNC2=C1C=CC(=C2)O
  • InChI=1S/C14H20N2O/c1-3-16(4-2)8-7-11-10-15-14-9-12(17)5-6-13(11)14/h5-6,9-10,15,17H,3-4,7-8H2,1-2H3
  • Key:BOLBZNHQIHKGON-UHFFFAOYSA-N

6-Hydroxy-DET, or 6-HO-DET, also known as 6-hydroxy-N,N-diethyltryptamine, is a possible psychedelic drug of the tryptamine family related to dimethyltryptamine (DMT). It is the 6-hydroxy derivative of diethyltryptamine (DET). The drug is a notable metabolite of DET.

Use and effects

According to Alexander Shulgin in his book TiHKAL (Tryptamines I Have Known and Loved), 6-HO-DET has been reported to be active at a dose of 10 mg by intramuscular injection. Lower doses of 1 to 2 mg were inactive, whereas 5 mg produced threshold effects. The drug at a dose of 10 mg was said to produce psychedelic effects very similar to those with 60 mg diethyltryptamine (DET), with these effects starting after 1 hour and lasting 2 to 3 hours. Based on this report, the drug would be about 5 to 6 times more potent than DET in humans. However, this report of 6-HO-DET's properties and effects is a second-hand early account in a single subject provided by Stephen Szara and colleagues and has not been replicated. Moreover, it is seemingly inconsistent with the inactivity of the closely related compounds 6-HO-DMT, 6-MeO-DMT, and 6-fluoro-DET. Relatedly, Shulgin wrote in TiHKAL that it is generally accepted that 6-HO-DET is inactive.

Interactions

Pharmacology

Pharmacodynamics

The effects of 6-HO-DET in animals have been studied. It was found to be much more potent than diethyltryptamine (DET) in terms of producing behavioral effects in rodents.

Pharmacokinetics

Alexander Shulgin has noted that 6-HO-DET may have poor blood–brain barrier permeability due to its exposed hydroxyl group and consequent polarity analogously to bufotenin (5-HO-DMT).

Chemistry

Properties

The predicted log P of 6-HO-DET is 3.1. For comparison, the predicted log P of 6-HO-DMT is 2.4, of 4-HO-DET is 2.7, of 5-HO-DET is 1.9, and of bufotenin (5-HO-DMT) is 1.2.

Analogues

Analogues of 6-HO-DET include diethyltryptamine (DET), 6-hydroxytryptamine (6-HT or 6-HO-T), 6-HO-DMT, 6-MeO-DMT, 6-methyl-DMT, 6-fluoro-DET, psilocin (4-HO-DMT), 4-HO-DET, bufotenin (5-HO-DMT), 7-HO-DMT, 5-HO-DET, 5-HO-DPT, and 5-HO-DiPT, among others.

History

6-HO-DET was first described in the scientific literature by Stephen Szara and colleagues by 1962. It was identified as a major active metabolite of diethyltryptamine (DET). In addition, they found that excretion of 6-HO-DET with DET administration correlated with DET's hallucinogenic effects and that 6-HO-DET was much more potent than DET in humans based on preliminary observations. Consequently, Szara and colleagues theorized that 6-hydroxylation of psychedelic tryptamines like dimethyltryptamine (DMT), DET, and α-methyltryptamine (AMT) was importantly involved in their hallucinogenic effects. However, this hypothesis was later found to be incorrect and was abandoned.

See also